Acute Myeloid Leukemia | Richard M Stone

published 6 days ago by Dr Neil Love

A special video supplement to a CME conference held during the 61st ASH Annual Meeting featuring expert comments on the management of acute myeloid leukemia. Featuring perspectives from Dr Richard M Stone. Design and results of the QUAZAR AML-001 maintenance trial assessing CC-486 versus placebo for patients with AML in first remission (00:00) Mechanism of action of azacitidine in AML (04:09) Preclinical data on the use of anti-inflammatory agents for clonal hematopoiesis of indeterminate potential (CHIP) (05:56) Ongoing investigations of anti-CD47 antibodies, antibody-drug conjugates and immune checkpoint inhibitors for AML (07:40) Clinical relevance of CHIP mutations (11:05) Pathophysiology of CHIP mutations and cardiovascular disease (16:23) Composition of CPX-351; advantages and disadvantages in the management of AML (17:45) Efficacy and safety of CPX-351 for secondary AML; patient selection for treatment with CPX-351 (20:10) Investigation of venetoclax-based combination strategies in AML (23:27) Factors determining eligibility for intensive chemotherapy for older and younger patients with AML (26:10) Counseling patients on potential outcomes of intensive chemotherapy for AML (30:51) Duration of therapy with an HMA and venetoclax for patients with AML (34:27) Genetic alterations in AML; incidence and biology of FLT3 mutations (36:12) Clinical presentation of patients with AML with FLT3 mutations; activity of the FLT3 inhibitors gilteritinib and midostaurin (38:44) Role of FLT3 inhibitors as a bridge to transplant and in the post-transplant setting (42:12) Tolerability of FLT3 inhibitors for patients with AML and choice of agent in the post-transplant maintenance setting (45:18) Evidence with and ongoing investigation of the FLT3 inhibitor quizartinib in patients with AML with a FLT3 mutation (47:28) Incidence of IDH mutations in AML; treatment for AML with IDH1 and IDH2 mutations (49:45) Differentiation syndrome with IDH inhibitors: Incidence, presentation and management (54:20) Treatment options for patients with AML harboring IDH or FLT3 mutations who are unfit for intensive chemotherapy (57:02) Future developments in the management of AML (59:28) Long-term outcomes with HMA and venetoclax in AML (1:01:32) CME information and select publications

more episodes from Research To Practice | Oncology Videos